Erythromycylamine

Erythromycylamine is a macrolide antibiotic. Erythromycylamine has antibacterial activity against most Gram-positive cocci and M. catarrhalis[1][2].

Product Specifications

CAS Number

[26116-56-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/erythromycylamine.html

Purity

97.0

Solubility

10 mM in DMSO|DMSO : ≥ 15mg/mL

Smiles

C[C@@H]([C@@H]([C@H](C(O[C@@H]([C@@](O)([C@@H]([C@H]([C@H]([C@@H](C[C@]1(O)C)C)N)C)O)C)CC)=O)C)O[C@H]2C[C@](C)([C@H]([C@@H](O2)C)O)OC)[C@H]1O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O

Molecular Formula

C37H70N2O12

Molecular Weight

734.96

Precautions

H302, H315, H319, H335

References & Citations

[1]Naik S, et al. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother. 1989 Sep;33 (9) :1614-6.|[2]Fernandes CJ, et al. Multi-centre collaborative study for the in vitro evaluation of new macrolides dirithromycin and erythromycylamine. Australian Group for Antimicrobial Resistance (AGAR) . Pathology. 1995 Jan;27 (1) :74-8.